Medtronic plc (MDT) Economic Moat Analysis50

Moat50

Equal-weight average of four evidence-backed rubric grades (0–4), scaled to 100.

structural advantage · 2/4 · Exclusive monitoring technology, achieved device clearances and long-lived implants establish differentiation and plausible continuity costs. They support a mixed structural assessment because the catalog does not show sustained comparative outcomes, replacement loyalty or a portfolio-wide barrier to competing products.

durability · 2/4 · BlueSync's presence in the 2024 and 2026 disclosures demonstrates continuing deployment, while implants and multiyear purchase commitments support some persistence. Patent expiry and historical industry share shifts limit confidence. Continued product availability is weaker evidence than sustained economic protection.

customer dependency · 2/4 · Implanted devices with remote monitoring support ongoing treatment relationships, and noncancellable minimum purchases establish some contractual dependence. The approximately $0.4 billion of remaining obligations at July 31, 2026 covers contracts originally lasting at least one year; it does not establish broad hospital or physician dependence.

erosion resilience · 2/4 · FY26 organic growth and new regulatory clearances demonstrate continued demand and product renewal despite a demanding competitive environment. Historical industry share shifts and procurement pressure temper that evidence. Aggregate growth does not establish share protection, and the historical consolidated scope includes MiniMed.

Pricing power—

Insufficient evidence for every rubric criterion; no category score is inferred.

realized pricing · — · The catalog discloses revenue growth, margin changes and procurement pressure but does not isolate realized selling-price changes. Neither stronger sales nor stable margins distinguishes price from volume, mix, costs or fiscal-calendar effects. The previous analysis's pricing claims cannot supply missing current evidence.

retention · 2/4 · Long-lived implants, device-linked monitoring, minimum-purchase commitments and FY26 organic growth indirectly support continuing demand. These are mixed retention indicators: treatment continuity and outstanding commitments do not demonstrate renewal rates, replacement loyalty or resistance to competitive procurement.

margin resilience · 2/4 · FY26 GAAP operating margin was flat while non-GAAP margin fell 130 basis points, with disclosed tariff and MiniMed payment impacts. Q1 FY27 subsequently improved both measures. This is mixed resilience, qualified by the extra fiscal week and MiniMed consolidation; pricing's contribution is unestablished.

contractual freedom · 1/4 · The disclosed purchasing environment makes competitive pricing essential, with provider consolidation, tender pricing and reimbursement cost controls constraining discretion over terms. These business conditions support a weak grade. Exact repricing rights and contract-level concessions are absent, so the extent of constraint remains unquantified.

Predictability94

5 consecutive published annual periods. Equal weights: nondeclining revenue frequency; revenue-growth volatility (5–40pp); positive FCF frequency; FCF-margin volatility (3–20pp). Stability indicator, not a growth forecast.

Nondeclining revenue years (%)

75.00

Revenue growth volatility (pp)

3.49

Positive FCF years (%)

100.00

FCF margin volatility (pp)

1.51

observedAnnualPeriods

5.00

Financial strength58

Equal-weight grades: debt/FCF (1–8x), net debt/earnings before interest and tax (0–5x), interest service (1–12x), current ratio (0.75–2x). Earnings use reported operating income, an original issuer-reported unadjusted EBIT reconciled to net income, income tax and signed net interest, or reported pretax profit plus reported gross interest expense. Reported EBIT is distinct from GAAP operating income and gross interest. Interest service uses earnings/interest expense; if unavailable, it uses reported operating cash flow/cash interest paid, without relabeling cash paid as accrued expense. Nonpositive cash flow/earnings score 0 for their service component; reported zero interest with a positive numerator scores 100. Net cash scores 100 for net leverage. Missing disclosures remain unavailable. General nonfinancial-company rubric, not a credit rating; exceptional and nonoperating gains are not normalized out. IFRS finance-cost and cash-flow classifications retain their reported scope.

debtFcfGrade

40.67

netDebtEbitGrade

19.55

interestCoverageGrade

73.13

currentRatioGrade

100.00

Debt / FCF (x)

5.15

Net debt / operating income (x)

4.02

Interest coverage (x)

9.04

Current ratio (x)

2.13

Capital allocation83

Three-year equal-weight indicators: pretax return on average invested capital (0–25%; equity + debt − cash, each year and its prior year), share-count growth (0–5%, lower better), share-based cost/revenue (2–20%, lower better), consolidated FCF/net income (0–1x). Return uses reported operating income, an original issuer-reported unadjusted EBIT reconciled to net income, income tax and signed net interest, or EBIT calculated from reported pretax profit plus reported gross interest expense; the issuer-reported EBIT is distinct from GAAP operating income and gross interest; exceptional/nonoperating gains are not normalized out. Share-based cost uses the reported cash-flow add-back or, if absent, separately reported recognized compensation expense; the latter never becomes an FCF adjustment. Nonpositive net income scores 0 for cash conversion; absent income/FCF stays unavailable. ROIC remains undefined for nonpositive invested capital; the explicit asset-return alternative does not change the ROIC chart. Missing financial inputs alone never trigger an alternative. Does not establish acquisition quality or buyback timing.

3-year pre-tax operating return (%)

7.84

3-year average dilution (%)

-1.21

3-year average SBC / revenue (%)

1.25

cashConversionGrade

100.00

Management63

Equal-weight average of four evidence-backed rubric grades (0–4), scaled to 100.

capital discipline · 2/4 · FY26 operating cash flow of $7.330 billion funded $1.904 billion of capital expenditure, leaving $5.426 billion before shareholder returns of $4.2 billion. Q1 FY27 acquisition spending and short-term borrowing increased. Actual funding discipline is demonstrated, but acquisition returns and post-separation allocation outcomes remain unproven.

incentive alignment · 3/4 · Actual ownership and retention compliance, salary-multiple ownership requirements, adopted clawbacks and conditional change-of-control vesting establish meaningful alignment mechanisms. Recent appointees have not reached ownership thresholds. These implemented safeguards support a strong grade without establishing exceptional realized pay-for-performance outcomes.

execution · 2/4 · FY26 organic growth, achieved clearances and completed MiniMed separation demonstrate operating and transaction delivery. Q1 growth offers additional indirect evidence but benefited from an extra week. FY26 adjusted-margin contraction and the absence of demonstrated separation benefits keep execution mixed rather than exceptional.

governance · 3/4 · All directors except the CEO are independent, annual board evaluations are disclosed, compensation-recovery policies are adopted, and shareholders actually approved compensation in an advisory vote. Combined chairman and CEO roles concentrate leadership. These safeguards support strong formal governance, with limited evidence of oversight effectiveness in difficult decisions.